Eli Lilly and Company (NYSE:LLY) Announces Quarterly Dividend of $1.73

Key Points

• Eli Lilly declared a quarterly dividend of $1.73 per share, with shareholders of record on May 15 (ex-dividend date May 15) to be paid on June 10, implying an annualized dividend of $6.92 and a yield of about 0.7%.
• The company reported a strong quarter, with EPS of $8.55 versus a $6.97 consensus and revenue of $19.80 billion (up 55.5% year-over-year), and issued FY2026 EPS guidance of $35.50–$37.00.
• Dividends appear well-covered: Lilly has raised its dividend for 11 consecutive years, a three-year average increase of 0.2% per year, and a current payout ratio of 23.3% (expected to fall to ~16.5% on analysts' next-year EPS estimates).

Eli Lilly and Company (NYSE:LLY - Get Free Report) announced a quarterly dividend on Monday, May 4th. Stockholders of record on Friday, May 15th will be paid a dividend of 1.73 per share on Wednesday, June 10th. This represents a c) annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th.

Eli Lilly and Company has increased its dividend payment by an average of 0.2%per year over the last three years and has increased its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a dividend payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Eli Lilly and Company to earn $41.97 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 16.5%.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $967.49 on Tuesday. The stock's fifty day moving average is $947.05 and its 200-day moving average is $987.36. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock has a market capitalization of $914.11 billion, a PE ratio of 34.37, a PEG ratio of 1.13 and a beta of 0.48. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business's revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 33.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after buying an additional 16 shares during the period. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $30,000. Finally, 10Elms LLP lifted its stake in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.